| Age | 67 ±7 (mean ± SD) | |
| PSA ng/l (median) | 17.0 (median) | 3.8 - 120 (range) |
| n= (%) | ||
| Clinically significant prostatecancer | Gleasongrade ≥ 3 + 4 | 57 (81) |
| Pre-treatment risk stratification for metastatic disease | Low | 5 (7) |
| Intermediate | 17 (25) | |
| High | 47 (68) | |
| Suspectedmetastasis (PSMA-PET) | Lymph node(s) | 18 (26) |
| Distant (M1a/b/c) | 11 (16) | |
| Treatment | RALP | 31 (45) |
| EBRT | 11 (16) | |
| ADT (including postponed) -with or without chemo- or radiotherapy | 18 (26) | |
| Active surveillance/WW | 9 (13) |